Join UT MD Anderson tomorrow at ESMO for Meet the Experts at Booth 8006 in Hall 8.
Connect with our experts to discuss KRAS-directed therapy, breast cancer care and next-generation immunotherapies. See Friday's full schedule: http://spr.ly/6011BHXHcN #ESMO26 #EndCancer
@mvnegrao @champiatMD
1574 浏览 · 8 赞 · 3 转发 · 1 回复
Calderasib monotherapy in various KRAS G12C–mutated advanced solid tumors: Results from the phase 1 KANDLELIT-001 study
https://esmocongress.esmo.orgKrascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer
https://esmocongress.esmo.orgFirst-line (1L) olomorasib + pembrolizumab in KRAS G12C-mutant NSCLC: Updated results from LOXO-RAS-20001 and SUNRAY-01
https://esmocongress.esmo.org- KRAS Kickers@KRASKickers
@UTMDAnderson Dr. @mvnegrao - the New Era of KRAS-directed therapy
来源：UT MD Anderson · x.com